Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s great news!! Just ask the promotion crew on this board !! Watch the spin!!
The insiders that sold tens of millions of dollars worth of stock should be doing that not a bagholder
The trading is not reflecting that
And down how much from the high?
Disregard ‘We’ as it should be fellow ‘bag holders’
What a Joke!! Look at the PPS and stop redirecting blame.
$65 trade. Makes no sense unless for tax loss purposes
I don’t think anyone is impressed with your evidence and or track record. And for the record we ( including me) all wish you were right just one time.
They cashed out for 100’s of millions but yet the company is running out of cash.
The management teams needs to give reasons for shorts to cover and for buyers to buy. They have done NOTHING for shareholder value but personally cashed out at inflated prices which at the time was on the hope of something they cannot deliver on. Failure is an understatement
The PPS is the proof!! What’s your proof of any claims which so far are 100% false ?
Refreshing and UPDATING your company’s Overview is NOT illegal.
CORPORATE OVERVIEW
Humanigen has discovered, developed, and plans to commercialize LENZ® (lenzilumab), a variant-agnostic immunomodulatory antibody, which addresses a significant unmet need in COVID-19.
https://ir.humanigen.com/English/overview/default.aspx
‘If’you are right
Delusion?
NO NO. According to some the management team has done everything perfectly!! They are padding themselves AGAIN at bagholders expense. It’s easier to fail and print free shares then it is to run a successful honest company such as HGEN!!
This will save capital. PPS $70 plus
‘It is false to contend that management touted lenz for covid after that. You are misrepresenting management's guidance’
But before that they did!! Wow, you are misleading and covering up facts. It’s on their website!! in their press releases’s !! Management has misrepresented their guidance and it’s shareholders!! Look at the PPS!!!
‘Where do you see management touting lenz for covid? They're not’.
Are you kidding us? Are you joking? It’s on almost every PR and on HGEN’s website !!!
https://www.humanigen.com/
March 24, 2022,
Updated NIH COVID-19 Treatment Guidelines
Updated NIH COVID-19 Treatment Guidelines include updated results and interpretation from lenzilumab LIVE-AIR study now published in The Lancet Respiratory Medicine. The updated interpretation of LIVE-AIR concludes “Lenzilumab improved ventilator-free survival in participants with hypoxemia who were not receiving MV, with the greatest benefit among those with lower CRP levels”, based on the increased incidence of ventilator-free survival observed in patients with CRP <150 mg/L (90% vs 79%, HR 2.54; 95% CI, 1.46–4.41; P=0.0009). Currently, lenzilumab is not yet authorized or approved but is available via compassionate use in some countries (learn more). Guidelines state that while GM-CSF is believed to be a key driver of lung inflammation in COVID-19 pneumonia, operating upstream of other pro-inflammatory cytokines and chemokines, NIH interpretation of clinical data show that lenzilumab is the only GM-CSF inhibitor to demonstrate a benefit in the treatment of COVID-19. Lenzilumab may mitigate inflammation by inhibiting this signaling axis upstream of IL-6 and IL-1 and thus minimizing downstream production of numerous pro-inflammatory mediators involved in the pathogenesis of COVID-19.
About Lenzilumab
Lenzilumab is a proprietary Humaneered® first-in-class monoclonal antibody that has been proven to neutralize GM-CSF with high specificity and affinity to prevent signaling through its receptor. GM-CSF along with RAS pathway mutations play key roles in CMML and other cancers, including juvenile myelomonocytic leukemia (JMML), myelodysplastic syndromes, myeloproliferative neoplasms, and acute myeloid leukemia.15,16,17 GM-CSF is also of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and common to chimeric antigen receptor T-cell (CAR-T) therapy, acute Graft versus Host Disease (aGvHD) and other indications.
Now that Covid is officially a NON event as per the CDC. When will HGEN concentrate on something they can effectively treat ? They failed on any and all claims with COVID so they need to STOP mentioning anything to do with COVID
If true, That would make sense which is why it’s NOT true
.15 cents. No $. Dilution to the tune of 10’s of millions of $ for insiders and bag holders hold the bag
Management has successfully done zero of any worth
We are a penny stock because of the inability of management
Enough on their plate? They have done nothing in the past 2 years to better shareholder value.
Scampo alert. Scam.. Fraud. LIES.
Scampo Scam alert
Agree
$72-$76
I have been for 2 plus years and own many shares as I took the gamble on averaging down
10k shares ? Step it up!!
Amended the annual report
As is the Stock itself.
Welcome to Scampo land. I tired to warn you and others but all failed to listen and defended the obvious
Scampo scam
They have been recycling the same BS for 10+ years. Total scam. First NEWC then VSYM and now the new one USPS.
On April 18, 2023, Humanigen, Inc. (the “Company”) was notified that it had been granted an extension until August 21, 2023 to demonstrate compliance with all applicable requirements for listing of the Company’s common stock on Nasdaq by the Nasdaq Hearings Panel (the “Panel”), subject to the Company’s compliance with the Panel’s requirements for periodic updates relating to the status of the Company’s progress against achievement of the compliance plan presented at the April 6, 2023 hearing with the Panel.
Great call!!!
Agree